THERANOVA-LIM: Optimizing the city hospital link to support patients on oral anticancer drugs

THERANOVA-LIM: Optimizing the city hospital link to support patients on oral anticancer drugs | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article THERANOVA-LIM: Optimizing the city hospital link to support patients on oral anticancer drugs Marion Boucheteil, Sophie Leobon, Kim-Arthur Baffert, Tiffany Darbas, and 9 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3890177/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Purpose: Recent developments in oral chemotherapy and targeted therapies have radically changed the way in which cancer patients are managed. Ambulatory care is now common, associated with the development of organizations that foster, secure home treatments, and reinforce the city hospital link. Methods: THERANOVA-LIM (NCT04931329), a prospective, interventional study, assessed the satisfaction of healthcare professionals and patients who benefited from improved access to information on appropriate drug use imparted by a drug vigilance card or a prescription with a QR code. Results: Initially, an e-questionnaire was used to explore the practices and expectations of retail pharmacists; only 40% stated that they felt comfortable when managing patients on oral therapy. A total of 128 patients were included in the study, 55 in a “medication vigilance card” group and 73 in a “prescription with QR code” group. Patients were satisfied with the new systems and with the simplicity afforded by both the card and the prescription (p = 0.8). Similarly, 93.2% of professionals were satisfied with the new system. However, they felt that the prescription with a QR code was of greater assistance than the drug vigilance card (p = 0.02). There was no significant between-group difference in compliance (p = 0.3595) Conclusion: The two systems improved the management of patients on oral chemotherapy; the QR-coded prescription was optimal. The fact that both patients and healthcare professionals were satisfied encourages us to extend the innovations and evaluate them further. Trial Registration Number and the date of registration: ClinicalTrials.gov, NCT04931329. 2021-05-10 Oral therapy cancer targeted therapies chemotherapy compliance safety Figures Figure 1 Figure 2 INTRODUCTION Recent developments in oral chemotherapy and targeted therapies have radically changed the management of cancer patients [ 1 ]. Intravenous drugs were traditionally administered in the hospital, but outpatient oral cancer treatments are now developing rapidly, encouraging patients, families, and medical teams to reconsider the hospital-centric model of care [ 2 , 3 ]. The French National Cancer Institute (INCa) estimated that the cost of anticancer drugs would attain 3.45 billion euro in 2021 [ 4 ] and estimated that, by 2020, oral anticancer drugs would represent half of the therapeutic oncological arsenal [ 5 ]. In 2018, more than 80 oral anticancer drugs were in the Oncology and Hematology pipeline [ 6 ]. Oral treatments offer several advantages that improve patient quality-of-life [ 7 ] and well-being [ 8 ] [ 9 ]. Patients usually prefer oral rather than intravenous drugs [ 10 ]. However, it is necessary to guarantee safe use [ 11 ]. The major risks include poor compliance, drug interactions, and toxicity [ 12 ]. Early detection of adverse effects can help avoid emergency hospitalization, non-adherence, or treatment discontinuation [ 13 ]. Healthcare organizations must be highly coordinated to ensure quality of care and patient safety as patients move between the city and the hospital [ 14 ]. Optimization of home care for cancer patients requires coordinated intervention by hospital and outpatient healthcare professionals who prevent, detect, and manage adverse events; avoid drug interactions; and counter drug misuse by educating patients, as advocated by the 2014–2019 Cancer Plan [ 6 ]. Interdisciplinary coordination of various healthcare players is essential to ensure optimal care. In Limousin, the proportion of the population aged over 70 years is higher than the national average (19 vs. 11%) [ 15 ]. In a recent evaluation performed during the COVID epidemic, we (of the oral therapy center) observed that one-third of patients were very comfortable with the new technologies, independent of caregiver opinions [ 16 ]. At that time, preliminary work in our department highlighted the utility of a drug vigilance card. This improved the city-hospital link during the treatment of chronic lymphocytic leukemia and chronic myeloid and multiple myeloma [ 17 ]. This work gave rise to the THERANOVA-LIM project (Oral Therapies in New Aquitaine and Limousin). The aim of this study was to evaluate communication between the city and the hospital via QR codes written on the drug vigilance cards or prescriptions of patients treated in the Onco-Hematology department. The QR codes provide information on new drugs to healthcare professionals, as do existing oral anticoagulant cards. MATERIALS AND METHODS Study design The THERANOVA-LIM study was a prospective, descriptive, non-interventional, single-center study. Initially, one group of patients were given drug vigilance cards; later, another group were given prescriptions with QR codes. Phase 1 (drug vigilance card) patients were enrolled from November 08, 2021, to April 07, 2022, and phase 2 (prescription) patients from June 01, 2022, to August 30, 2022. The inclusion criteria were: treatment at the oral therapy center of the oncology department of Limoges University Hospital [ 18 , 19 ]; at least one oral chemotherapy and/or targeted therapy; and the ability to speak and understand French. The exclusion criteria were: endocrine therapy alone (excluding the new-generation therapies [abiraterone and enzalutamide] used to treat prostate cancer); injectable therapy alone; and a lack of Internet access required to activate the card, and/or a cell phone. Scanning the QR code directs the patient to a dedicated online platform [ 20 ] and to the Association d'Oncologie Médicale et de Radiothérapie (AOMR) website that features cards and prescriptions [ 21 ]. Both patient groups could access written advice on the prescribed drugs and instructions for use prepared by our oncologist. For technical reasons, the sites for both groups differed. In contrast to the AOMR site, the card platform also contained patient medical information. The time course of the study is shown in Fig. 1 . Objectives and assessment criteria The main objective was to measure patient satisfaction at 3 months (M3) using a paper or e-questionnaire with 12 questions adapted from the Computerized System Usability Questionnaire (CSUQ); all answers were scored on a 7-point Likert scale [ 22 ]. The questions were adapted from previous publications [ 17 , 23 ]. The secondary objectives were to measure patient compliance [ 24 ] and the satisfaction of healthcare professionals at M3. A link to the e-questionnaire was sent via e-mail; the survey could be completed only once from that IP address. All questionnaire replies (online and paper) were anonymous. Human Ethics and Consent to Participate This research was carried out in compliance with the French law n°2012 − 300 of March 5, 2012 relating to research involving the human person and the Declaration of Helsinki (which can be found in its full version on the website http://www.wma.net/en/30publications/10policies/b3/).Thi s research was approved by the Comité de Protection des Personnes (approval no. 2021-A01230-41). The study is registered with ClinicalTrials.gov, NCT04931329. All patients enrolled in the study provided written informed consent. Statistical analysis Given the lack of data on this subject and on this new-generation card, it was decided to include all eligible patients. All data were collected and analyzed using R software (version 4.1.1; R Foundation for Statistical Computing, Vienna, Austria). Quantitative variables are expressed as numbers, medians with minima, and maxima, or means with standard deviations. Qualitative variables are expressed as numbers with percentages. To study the relationships between different variables (via bivariate analysis), we used the Mann-Whitney test to compare the scores of the two groups. The chi-square test was employed to compare qualitative variables. All significance thresholds were set to 5%. All patients who consulted during the study period and who met the eligibility criteria and wished to participate were included. RESULTS Preliminary survey of pharmacists An e-questionnaire was used to establish pharmacist practices and expectations; 46 pharmacists replied, of whom only 40.0% stated said they felt comfortable when managing a patient on oral therapy. Only 30 (62.0%) were familiar with the anticancer drug use sheets; 43.0% (n = 15) consulted them regularly and 58.0% (n = 19) printed them for patients when the drugs were first dispensed. Almost 20.0% (n = 9) said they were in regular contact with the oncology department, and 69.6% (n = 32) that they were contacted by patients who experienced adverse events related to cancer treatment. Only 8.7% (n = 4) of city pharmacies scheduled oral therapy follow-up interviews within their business premises. Healthcare professionals lacked knowledge of and training on anticancer drugs, attributable to the rapid development of new agents and the complexity of the protocols. It was acknowledged that communication between independent professionals and hospital departments was suboptimal. Clinicopathological characteristics of patients A total of 128 patients were included, 55 in the “drug vigilance card” and 73 in the “prescription with QR code” group (Fig. 2 ). The clinicopathological characteristics are presented in Table 1 and were comparable between the two groups. The median age at inclusion was 69 years (range 37–90 years); there were 85 women and 43 men. The majority of patients lived as couples (89.1%) in single-family homes (87.3%), were retired (74.8%), and resided in the University Hospital Center area (64.6%). The three most common cancers were breast (37.5%), prostate (14.1%), and brain (10.9%) cancers. The vast majority of patients had metastatic cancer (90%) and grade IV gliomas (brain tumors) (85%). Table 1 Clinicopathological characteristics of patients Whole population Phase 1 (drug vigilance card) phase 2 (prescription) p-values Total, n (%) 128 (100) 55 (43) 73 (57) Median age at inclusion, years (min-max) 69 (37–91) 69 (37–91) 70 (38–89) 0.1852 Female/ Male 85 (66.4) / 43 (33.6) 39 (70.9) / 16 (29.1) 46 (63.0) / 27 (37.0) 0.4549 Performans status at baseline n (%) 0 37 (28.9) 14 (25.5) 23 (31.5) 0.4764 1 75 (58.6) 36 (65.5) 39 (53.4) 2 15 (11.7) 5 (9.0) 10 (13.7) 3 1 (0.8) 0 1 (1.4) Lifestyle* Single/ In couple 20 (15.9) / 106 (84.1) 6 (10.9) / 49 (89.1) 14 (19.7) / 57 (80.3) 0.2927 Apartment/ house/ lodging 14 (11.1) / 110 (87.3) / 2 (1.6) 5 (9.1) / 50 (90.9) / 0 9 (12.7) /60 (84.5) / 2 (2.8) 0.3091 Lives in the University Hospital Center area Yes/No 82 (64.6) / 46 (35.4) 35 (63.6) / 20 (36.4) 47 (64.4) / 33 (35.6) 1 Retired/ In work/ On disability 95 (74.8) / 27 (21.3) / 5 (3.9) 40 (74.1) / 14 (25.9) / 0 55 (75.3) / 13 (17.8) / 5 (6.8) 0.112 Cancer site n (%) Cardia 1 (0.8) 0 1 (1.4) 0.4232 Colon 10 (7.8) 7 (12.7) 3 (4.1) Endometrium 1 (0.8) 0 1 (1.4) Ovary 12 (9.4) 5 (9.1) 7 (9.6) Pancreas 3 (2.3) 2 (3.6) 1 (1.4) Prostate 18 (14.1) 5 (9.1) 13 (17.8) Rectum 3 (2.3) 1 (1.8) 2 (2.7) Kidney 12 (9.4) 6 (10.9) 6 (8.2) Breast 48 (37.5) 21 (38.2) 27 (37.0) Brain tumors 14 (10.9) 7 (12.7) 7 (9.6) Adrenal 2 (1.6) 0 2 (2.7) Biliary tract 4 (3.1) 1 (1.8) 3 (4.1) Stage at inclusion of gliomas (n = 14) Grade III 2 (15) 1 (14) 1 (14) 0.8534 Grade IV 12 (85) 6 (86) 6 (86) Stage at inclusion excluding gliomas (n = 114) Stade I-III 11 (10) 2 (4) 9 (14) 0.0018 Stade IV 103 (90) 46 (96) 57 (86) Metastatic from the outset No 86 (67.2) 33 (60.0) 53 (72.6) 0.1891 Yes 42 (32.8) 22 (40.0) 20 (27.4) Situation at baseline Adjuvant setting 25 (19.5) 9 (16.4) 16 (21.9) 0.5758 Metastatic settint 103 (80.5) 46 (83.6) 57 (78.1) * Missing data Inclusion and follow-up The treatments are shown in Table 2 . The four most prescribed drugs were capecitabine (21.1%), ribociclib (11.7%), temozolomide (11.7%), and trifluridine/tipiracil (7.8%). In 43.0% of cases, it was necessary to modify the drug dose during the management. Of the phase 1 group, 83.6% attended hospital pharmaceutical appointments; the figure for the phase 2 group was 28.8% (p < 0.001). The numbers of telephone calls made by the oral therapy center were identical for both groups. During the study, 25.0% of patients experienced grade III or IV toxicities that were reported to pharmacovigilance; 6 (4.7%) were admitted to the emergency department, 11 (8.6%) were hospitalized, and 10 (11.1%) had to permanently cease treatment. No toxic deaths occurred. Table 2 Treatment received by the patients Whole population Phase 1 (drug vigilance card) Phase 2 (prescription) p-values Total, n (%) 128 (100) 55 (43) 73 (57) Oral therapy, n (%) Abemaciclib 5 (3.9) 2 (3.6) 3 (4.1) 0.06865 Abiraterone 9 (7.0) 4 (7.3) 5 (6.8) Axitinib 6 (4.7) 3 (5.3) 3 (4.1) Cabozantinib 4 (3.1) 2 (3.6) 2 (2.7) Capecitabine 27 (21.1) 9 (16.4) 18 (24.7) Enzalutamide 9 (7.0) 1 (1.8) 8 (11.0) Everolimus 2 (1.6) 2 (3.6) 0 Lenvatinib 1 (0.8) 0 1 (1.4) Niraparib 9 (7.0) 5 (9.1) 4 (5.5) Olaparib 4 (3.1) 1 (1.8) 3 (4.1) Palbociclib 5 (3.9) 1 (1.8) 4 (5.5) Pazopanib 1 (0.8) 0 1 (1.4) Regorafenib 1 (0.8) 1 (1.8) 0 Ribociclib 15 (11.7) 9 (16.4) 6 (8.2) Sorafenib 1 (0.8) 0 1 (1.4) Sutinib 2 (1.6) 1 (1.8) 1 (1.4) Temozolomide 15 (11.7) 7 (12.7) 8 (11.0) Trifluridine/tipiracil 10 (7.8) 6 (10.9) 4 (5.5) Vinorelbine 2 (1.6) 1 (1.8) 1 (1.4) Prescription procedures, n (%) Early access 2 (1.6) 0 2 (2.7) 0.4113 Clinical trial 2 (1.6) 1 (1.9) 1 (1.4) Routine pratice 124 (96.9 54 (98.1) 70 (95.9) Adjusting the dose of prescribed treatment, n (%) No 73 (57.0) 29 (52.7) 44 (60.3) 0.5006 Yes 55 (43.0) 26 (47.3) 29 (39.7) Pharmaceutical consultation, n (%) No 61 (47.7) 9 (16.4) 52 (71.2) < 0.001 Yes 67 (52.3) 46 (83.6) 21 (28.8) Number of center calls, median (min-max) 6 (0–20) 7 (0–15) 6 (1–20) 0.4868 Toxicity III-IV reported to pharmacovigilance, n (%) No 96 (75.0) 39 (70.9) 57 (78.1) 0.4627 Yes 32 (25.0) 16 (29.1) 16 (21.9) Emergency room visits for toxicity, n (%) No 122 (95.3) 52 (94.5) 70 (95.9) 1 Yes 6 (4.7) 3 (5.5) 3 (4.1) Hospitalization for toxicity, n (%) No 117 (91.4) 49 (89.1) 68 (93.2) 0.6222 Yes 11 (8.6) 6 (10.9) 5 (6.8) Permanent discontinuation of treatment due to toxicity, n (%) No 80 (88.9) 40 (88.9) 40 (88.9) 0.0816 Yes 10 (11.1) 5 (11.1) 5 (11.1) Assessing patient satisfaction Of the 119 patients who could be evaluated (9 died during the study: 7 during phase 1 and 2 during phase 2), the questionnaire response rates were 37.0% (n = 44); 25.0% (n = 12/48) for phase 1 and 45.0% (n = 32/71) for the phase 2 groups (Fig. 2 ). The principal results are shown in Table 3 . Patients in both groups were generally satisfied with the system and the ease of use of both the card and the prescription (p = 0.9). Of patients with QR codes on vigilance cards, 100% presented their cards to dispensing pharmacists, 28.6% to referring GPs, and 28.6% to home care nurses. The occasions on which patients presented cards included medical consultations (25.0%), visits to the pharmacy (100%), and when the homecare nurse was in attendance (25.0%). Patients with QR codes on their prescriptions presented those prescriptions in 72% of cases, 88.5% (n = 23/26) to dispensing pharmacists, 36.0% (n = 9/25) to GPs, and 29.6% (n = 8/27) to home care nurses. The occasions on which patients presented cards included medical consultations (33.3%), visits to the pharmacy (81.5%), when the homecare nurse was present (70.4%), during hospitalization (7.4%), and in emergency situations (3.7%). Table 3 Patient satisfaction at 3 months. Whole population Phase 1 (drug vigilance card) Phase 2 (prescription) p-value Total, n (%) 44 (100) 12 (27) 32 (72) 1. In general, I'm satisfied with this system (n = 37) median (min-max) 7 (2–7) 6 (5–7) 7 (2–7) .8970 2. In general, I'm satisfied with the ease of use of this system (n = 36) median (min-max) 7 (2–7) 6 (4–7) 7 (2–7) .4603 3. This system is easy to use (n = 36) median (min-max) 7 (2–7) 7 (3–7) 7 (2–7) .3922 4. I feel comfortable with this system (n = 37) median (min-max) 6 (1–7) 6 (4–7) 7 (1–7) .6732 5. It was easy to understand how to use this system (n = 37) median (min-max) 6 (1–7) 6 (3–7) 7 (1–7) .6265 6. When I made a mistake, it was quick and easy to correct it (n = 34) median (min-max) 6 (4–7) 6 (4–7) NA 7. I easily found the information I was looking for (n = 35) median (min-max) 6 (2–7) 6 (5–7) 7 (2–7) .8348 8. The system's information is easy to understand (n = 35) median (min-max) 7 (2–7) 6 (5–7) 7 (2–7) .9308 9. System screens are clearly organized (n = 35) median (min-max) 6 (4–7) 6 (4–7) NA 10. L’interface de ce système est agréable (n = 35) median (min-max) 6 (4–7) 6 (4–7) NA 11. I like using the interface of this system (n = 35) median (min-max) 6 (4–7) 6 (4–7) NA 12. This system has all the functions and potential I was looking for (n = 35) median (min-max) 7 (1–7) 6 (4–7) 7 (1–7) .8621 13. Did you show your card/prescription? No 9 20.5% 5 41.7% 4 12.5% .0661 Yes 35 79.5% 7 58.3% 28 87.5% 14. If yes, have you shown it to your doctor? (n = 32) No 21 65.6% 5 71.4% 16 64% .3988 Yes 11 34.4% 2 28.6% 9 36% If so, have you shown it to your pharmacist? (n = 33) No 3 9.1% 0 0% 3 11.5% .2026 Yes 30 90.9% 7 100% 23 88.5% If so, did you show it to your nurse? (n = 34) No 24 70.6% 5 71.4% 19 70.4% .1852 Yes 10 29.4% 2 28.6% 8 29.6% If yes, I have shown it during hospitalization (n = 35) No 33 94.3% 8 100% 25 92.6% .3262 Yes 2 5.7% 0 0% 2 7.4% If yes, I've shown it in emergency situations (n = 35) No 34 97.1% 8 100% 26 96.3% .3766 Yes 1 2.9% 0 0% 1 3.7% If yes, I showed it during a consultation (n = 35) No 24 68.6% 6 75% 18 66.7% .3948 Yes 11 31.4% 2 25% 9 33.3% If so, I showed it to the pharmacy: (n = 35) No 5 14.3% 0 0% 5 18.5% .2 Yes 30 85.7% 8 100% 22 81.5% If yes, did I show it to my nurse? (n = 35) No 25 71.4% 6 75% 19 70.4% .419 Yes 10 28.6% 2 25% 8 29.6% 15. Has this prescription/card helped you remember to take your medication? (n = 31) median (min-max) 5 (1–10) 5 (1–10) 5 (1–10) .2826 16. Has the presence of a QR code on this card/ prescription been useful? (n = 31) median (min-max) 7 (1–10) 7 (1–10) 5 (1–10) .8635 NA : not applicable Questionnaire based on a 7-point Likert scale ranging from disagreement (0) to total agreement (7) and 10 points (*). The satisfaction of healthcare professionals A total of 74 evaluations were collected (Table 4 ). Healthcare professionals were equally satisfied with the two QR code systems (100% vs. 91.7%). The QR code affixed to the prescription was, however, easier to access (64.3% vs. 91.7%, p = 0.02). Table 4 The satisfaction of healthcare professionals at 3 months. Whole population Phase 1 (drug vigilance card) Phase 2 (prescription) p-value Total, n (%) 74 (100) 14 (18.9) 60 (81) Did you know that your patient has a drug card / prescription with QR code? No 13 (17.6) 0 13 (21.7) .1274 Yes 61 (82.4) 14 (100) 47 (78.3) Has your patient shown you his drug card/prescription with QR code? No 31 (41.9) 9 (64.3) 22 (36.6) .1129 Yes 43 (58.1) 5 (35.7) 38 (63.3) Did the card or QR code prescription have an impact on this patient's care? No 26 (35.1) 3 (21.4) 23 (38.3) .3777 Yes 48 (64.9) 11 (78.6) 37 (61.7) If yes. has it had an impact on treatment information and management? No 11 (23.9) 5 (45.5) 6 (17.1) .1298 Yes 35 (76.1) 6 (54.5) 29 (82.0) If yes. has it had an impact on the risks associated with this treatment? * No 6 (13) 2 (18.2) 4 (11.4) .9466 Yes 40 (87) 9 (81.8) 31 (88.6) If yes. did it have an impact on information on how to proceed with this treatment? * No 10 (21.7) 4 (36.4) 6 (17.1) .3528 Yes 36 (78.3) 7 (63.6) 29 (82.9) In general. I'm satisfied with this system No 5 (6.8) 0 5 (8.3) .5980 Yes 69 (93.2) 14 (100) 55 (91.7) In general. I'm satisfied with the ease of use of this system No 10 (13.5) 5 (35.7) 5 (8.3) .0246 Yes 64 (86.5) 9 (64.3) 55 (91.7) * 2 missing data Compliance The compliance rates were 75.0% in the phase 1 group (n = 9/12) (drug vigilance card) and 59.4% (n = 19/32) in the phase 2 group (QR code on prescription); compliance rates did not differ significantly (p = 0.4). DISCUSSION We sought to strengthen the city-hospital link by placing a QR code on either a drug vigilance card or a prescription written by the oncology department, and we showed the feasibility of the approach. In terms of both ease of implementation and the satisfaction of healthcare professionals, the QR-coded prescription was optimal. Digitization in cases of complex care required by patients with chronic illnesses, particularly cancer, is essential [ 25 ]. Efforts to improve information sharing and coordination between hospitals and patients/pharmacists have been underway for several years. Cards have been developed for patients on anticoagulants [ 26 ]. The Dijon and Besançon university hospitals have created “identity cards” for diabetics [ 27 ] that feature a QR code indicating the required treatment, particularly in the event of an emergency [ 28 ]. The QR code system has been but little used by oncologists who require access to medical data or specific patient information. [ 29 , 30 ]. In our model, we integrated treatment information, data on urgent toxicity management, and advice; we sought to increase patient compliance. In the absence of medical consultation, a pharmacy is the place where health professionals are available without appointment; pharmacists must have timely and detailed information to ensure optimal care. Pharmacies are widespread and play key roles in care, particularly when patients require security and support. The coded QR card may seem interesting, particularly in terms of its format, because patients can carry coded QR cards at all times, but this does not mean that they are autonomous. Both the digital divide and difficulties in accessing technology are still in play. Even the average age of our population is similar to that nationally [ 15 ], the impact of age and access to new technologies must be particularly taken into account. Some studies on remote monitoring, particularly of oral therapy, included much younger patients [ 31 , 32 ]. For example, in the Capri study, the median age was 62 years (range 20–92 years); 27.7% of patients were aged between 65 and 74 years and 14% over 75 years [ 31 ]. The proportions of patients who use new technologies, particularly smartphone applications, are often age-dependent [ 31 , 33 , 34 ]. On the contrary, prescriptions are easy to use at any age. A limitation of the QR code system for prescription is that it applies only to drugs dispensed in hospitals, not community pharmacies, the staff of which thus lack knowledge of cancer treatments such as temozolomide. Website and smartphone applications aid symptom management. In a review, Penedo et al. found that e-Health technologies aided cancer treatment [ 35 ]. However, if such systems are exclusively patient-centric, they will not be accessible by healthcare professionals. We cannot assess whether the use of QR codes reduced the incidence and impact of toxicity; the study was not designed to answer this question. However, the toxicity rate of 25.0% is in line with the literature [ 31 ] and the number of toxicity management calls was lower than in our previous publication [ 18 ]. We thus highlight that healthcare professionals must improve city-hospital relationships and establish secure information systems for oral therapy [ 36 , 37 ]. Communication among healthcare professionals is vital [ 38 ]; presently, no optimal support system is available [ 39 ]. Occhipinti et al. showed that, although 44.4% of institutions had established city-hospital coordination, all found that this was time-consuming [ 40 ]. The monocentric nature of the present study is one limitation, particularly in terms of representativeness. The fact that the study was performed in two successive phases reflects technical imperatives; it was necessary both to create cards and develop software that placed QR codes on prescription. Moreover, self-questionnaires may introduce information bias. Indeed, some patients chose not to answer certain questions. In addition, a Hawthorne effect may be in play; patients who are aware that they are being surveyed may (consciously or unconsciously) overestimate their compliance rates [ 41 ]. Recruitment bias may be in play; many patients had brain tumors (our center has expertise in this field) [ 18 , 42 ]. However, unlike other studies, we did not select particular types of tumors and the QR code was available to all cancer patients. CONCLUSION We evaluated two systems with integrated QR codes (with prescription or cards); the prescription was preferred by both patients and professionals. This provides access to information on the correct and safe use of drugs. We developed a website that distributes QR codes free of charge; those who prescribe cancer treatment can place specific QR codes on their prescriptions. Once flashed, the QR codes redirects to the advice sheets on the websites of learned societies and official organizations. After scanning the QR codes on prescriptions, patients, caregivers, and healthcare professionals instantly access advice sheets. The system will be evaluated further by healthcare professionals. The increased availability of most oral anticancer drugs outside hospitals requires greater collaboration between hospital and primary care professionals, particularly dispensing pharmacists. It is essential to improve the continuity of care. Declarations Data availability Data are available from the corresponding author upon reasonable request Conflict of Interest The authors declare that they have no conflict of interest in relation to this study. Acknowledgements This work was funded by the Ligue Contre le Cancer, ALAIR, Accord Pharmafield, AstraZeneca, Janssen, Seagen, Crédit Mutuel Loire-Atlantique, and the ERRE family. The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/yM1QiD AUTHOR CONTRIBUTIONS Conceptualisation, E.D.; methodology, E.D.,SL.; formal analysis, S.L .; writing - original draft preparation, M.B, E.D, S,L.; writing - review and editing, M.B, S.L, K-A.B,T.D,C.P, V.L-B, J.P, L.V, F.T S.H, J.J,M.T,E.D ; supervision, E.D. All authors have read and agreed to the published version of the manuscript. References O’Neill VJ, Twelves CJ (2002) Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 87:933–937. https://doi.org/10.1038/sj.bjc.6600591 Bosco-Lévy P, de Boissieu P, Gouverneur A, et al (2017) National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study. Pharmacoepidemiol Drug Saf 26:1233–1241. https://doi.org/10.1002/pds.4282 Moreira A, Bernardo C, Ramos C, et al (2022) National trends in the use of oral chemotherapy over 13 years. Front Pharmacol 13:909948. https://doi.org/10.3389/fphar.2022.909948 Chiffres clés de la chimiothérapie - Chimiothérapie. https://www.e-cancer.fr/Professionnels-de-sante/Les-traitements/Chimiotherapie/Chiffres-cles-de-la-chimiotherapie. Accessed 9 Sep 2023 Plan Cancer 2014-2019 - Ref : PLANKPNRT14. https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Plan-Cancer-2014-2019. Accessed 9 Sep 2023 Le Plan cancer 2014-2019 - Les Plans cancer Jacobs JM, Ream ME, Pensak N, et al (2019) Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life. J Natl Compr Cancer Netw JNCCN 17:221–228. https://doi.org/10.6004/jnccn.2018.7098 Eilers J, Million R (2011) Clinical update: prevention and management of oral mucositis in patients with cancer. Semin Oncol Nurs 27:e1-16. https://doi.org/10.1016/j.soncn.2011.08.001 Rubenstein EB, Peterson DE, Schubert M, et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046. https://doi.org/10.1002/cncr.20163 Eek D, Krohe M, Mazar I, et al (2016) Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence 10:1609–1621. https://doi.org/10.2147/PPA.S106629 Ranchon F, Bouret C, Charpiat B, Leboucher G (2009) Sécurisation de l’emploi des chimiothérapies anticancéreuses administrables par voie orale. Pharm Hosp 44:36–44. https://doi.org/10.1016/j.phhp.2008.12.002 Masson E Parcours de soins : modélisation et analyse des risques induits par les anticancéreux oraux. In: EM-Consulte. https://www.em-consulte.com/article/1048739/parcours-de-soins�-modelisation-et-analyse-des-ris. Accessed 5 Sep 2023 Palmer DH, Johnson PJ (2015) Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. Cancer Metastasis Rev 34:497–509. https://doi.org/10.1007/s10555-015-9580-2 Schneider SM, Hess K, Gosselin T (2011) Interventions to promote adherence with oral agents. Semin Oncol Nurs 27:133–141. https://doi.org/10.1016/j.soncn.2011.02.005 Pyramide des âges. //extranet.dst.dk/websites/pyramide/pyramide.htm. Accessed 9 Sep 2023 Baffert K-A, Darbas T, Lebrun-Ly V, et al (2021) Quality of Life of Patients With Cancer During the COVID-19 Pandemic. In Vivo 35:663–670. https://doi.org/10.21873/invivo.12306 Touati M, Dumond-Wibaux É, Jeannet L, et al (2018) Carte vigilance médicament : le patient acteur de sa prise en charge Deluche E, Darbas T, Bourcier K, et al (2020) Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme). Med Oncol 37:69. https://doi.org/10.1007/s12032-020-01393-7 Deluche E, Darbas T, Bourcier K, et al (2020) CN46 Real-life experience of nurses coordinating device in oral therapy center (DICTO program). Ann Oncol 31:S1141. https://doi.org/10.1016/j.annonc.2020.08.2156 ID1life website. In: ID1 - Infos Urgence. https://www.id1.life/. Accessed 9 Sep 2023 AOMR website. https://www.cancer-limoges.fr/centre-des-therapies-orales/role-et-fonctionnement-du-cto. Accessed 9 Sep 2023 IBM computer usability satisfaction questionnaires: Psychometric evaluation and instructions for use: International Journal of Human–Computer Interaction: Vol 7, No 1. https://www.tandfonline.com/doi/abs/10.1080/10447319509526110. Accessed 2 Sep 2023 Poinsot R, Altmeyer A, Conroy T, et al (2006) [Multisite validation study of questionnaire assessing out-patient satisfaction with care questionnaire in ambulatory chemotherapy or radiotherapy treatment]. Bull Cancer (Paris) 93:315–327 GIRERD X, HANON O, ANAGNOSTOPOULOS K, et al (2001) Evaluation de l’observance du traitement antihypertenseur par un questionnaire : mise au point et utilisation dans un service spécialisé. Eval Obs Trait Antihypertenseur Par Un Quest Mise Au Point Util Dans Un Serv Spéc 30:1044–1048 Steinhubl SR, Muse ED, Topol EJ (2013) Can Mobile Health Technologies Transform Health Care? JAMA 310:2395–2396. https://doi.org/10.1001/jama.2013.281078 Gras-Champel V, Voyer A, Lematte C, et al (2005) Evaluation à l’occasion de leur hospitalisation de la qualité de l’anticoagulation orale chez des patients traités par antivitamines K. Therapies 60:149–157. https://doi.org/10.2515/therapie:2005019 Diabete-Infos (2019) Carte iDiabète. In: Diabète Infos. https://diabete-infos.fr/carte-idiabete/. Accessed 5 Sep 2023 urps-secretariat Lancement de la carte iDiabète – URPS. https://urps-pharmaciens-bfc.com/lancement-de-la-carte-idiabete/. Accessed 5 Sep 2023 Upton J, Olsson-Brown A, Marshall E, Sacco J (2017) Using QR codes to enable quick access to information in acute cancer care. Br J Nurs 26:S4–S12. https://doi.org/10.12968/bjon.2017.26.10.S4 Mittal A, Kum F, Rice M, et al (2022) An innovative use of Quick Response codes to provide patients information in Urology. J Clin Urol 20514158221092183. https://doi.org/10.1177/20514158221092183 Mir O, Ferrua M, Fourcade A, et al (2022) Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med 28:1224–1231. https://doi.org/10.1038/s41591-022-01788-1 Girault A, Ferrua M, Lalloué B, et al (2015) Internet-based technologies to improve cancer care coordination: current use and attitudes among cancer patients. Eur J Cancer Oxf Engl 1990 51:551–557. https://doi.org/10.1016/j.ejca.2014.12.001 Potdar R, Thomas A, DiMeglio M, et al (2020) Access to internet, smartphone usage, and acceptability of mobile health technology among cancer patients. Support Care Cancer 28:5455–5461. https://doi.org/10.1007/s00520-020-05393-1 Bizot A, Karimi M, Rassy E, et al (2021) Multicenter evaluation of breast cancer patients’’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. Br J Cancer 125:1486–1493. https://doi.org/10.1038/s41416-021-01555-y Penedo FJ, Oswald LB, Kronenfeld JP, et al (2020) The increasing value of eHealth in the delivery of patient-centred cancer care. Lancet Oncol 21:e240–e251. https://doi.org/10.1016/S1470-2045(20)30021-8 Renard P-Y (2013) Délivrance des anticancéreux oraux : besoins et attentes du pharmacien d’officine. Actual Pharm 52:44–47. https://doi.org/10.1016/j.actpha.2012.12.005 Abbott R, Edwards S, Whelan M, et al (2014) Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada. J Oncol Pharm Pract 20:29–39. https://doi.org/10.1177/1078155213504975 Maritaz C, Gault N, Roy C, et al (2019) Impact d’une organisation régionale coordonnée pour sécuriser la prise en charge des patients sous anticancéreux oraux : CHIMORAL, une étude comparative. Bull Cancer (Paris) 106:734–746. https://doi.org/10.1016/j.bulcan.2019.03.019 Seguin L, Tassy L (2022) E-santé, digitalisation ou transformation numérique : impact sur les soins de support en oncologie. Bull Cancer (Paris) 109:598–611. https://doi.org/10.1016/j.bulcan.2021.08.015 Occhipinti S, Petit-Jean E, Pinguet F, et al (2017) Implication du pharmacien dans l’accompagnement des patients sous anticancéreux oraux : état des lieux dans les centres de lutte contre le cancer (CLCC). Bull Cancer (Paris) 104:727–734. https://doi.org/10.1016/j.bulcan.2017.06.012 Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56–66. https://doi.org/10.3322/caac.20004 Pinet S, Durand S, Perani A, et al (2023) Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital. Front Oncol 13:1104659. https://doi.org/10.3389/fonc.2023.1104659 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3890177","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":269806569,"identity":"9bd193fb-9c38-49e1-9454-9a25754aaded","order_by":0,"name":"Marion Boucheteil","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Marion","middleName":"","lastName":"Boucheteil","suffix":""},{"id":269806570,"identity":"e71bb192-ee84-450e-9133-191a31e981ca","order_by":1,"name":"Sophie Leobon","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Sophie","middleName":"","lastName":"Leobon","suffix":""},{"id":269806571,"identity":"9dc15e9d-a57a-4a8e-815f-47ccbbe1f6c5","order_by":2,"name":"Kim-Arthur Baffert","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Kim-Arthur","middleName":"","lastName":"Baffert","suffix":""},{"id":269806572,"identity":"54bd38ca-171b-44b6-93fb-3f13733ce058","order_by":3,"name":"Tiffany Darbas","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Tiffany","middleName":"","lastName":"Darbas","suffix":""},{"id":269806573,"identity":"98b058fa-3224-4177-80c8-c39df4d74c7a","order_by":4,"name":"Clémentine Peyramaure","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Clémentine","middleName":"","lastName":"Peyramaure","suffix":""},{"id":269806574,"identity":"baecff81-8eb6-4dba-a6b9-857beb2c5657","order_by":5,"name":"Valérie Le brun-Ly","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Valérie","middleName":"Le","lastName":"brun-Ly","suffix":""},{"id":269806575,"identity":"ae7e3dea-a084-477a-aade-d9432fa96e64","order_by":6,"name":"Julia Pestre","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Julia","middleName":"","lastName":"Pestre","suffix":""},{"id":269806576,"identity":"8b3b0edc-d4a1-4958-8c02-3e3e5efb3e7d","order_by":7,"name":"Laurence Venat","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Laurence","middleName":"","lastName":"Venat","suffix":""},{"id":269806577,"identity":"059bcb14-cceb-462f-a3e0-5b2b231cbf87","order_by":8,"name":"Frédéric Thuillier","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Frédéric","middleName":"","lastName":"Thuillier","suffix":""},{"id":269806578,"identity":"0df870a1-78c1-421e-b349-5fe77278214a","order_by":9,"name":"Soline HUET","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Soline","middleName":"","lastName":"HUET","suffix":""},{"id":269806579,"identity":"9538f095-b525-402d-b9bd-608555ec95df","order_by":10,"name":"Jeremy Jost","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Jeremy","middleName":"","lastName":"Jost","suffix":""},{"id":269806580,"identity":"19cc970c-e7e4-4b62-8d37-aab29b0bbdb2","order_by":11,"name":"Mohamed Touati","email":"","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":false,"prefix":"","firstName":"Mohamed","middleName":"","lastName":"Touati","suffix":""},{"id":269806581,"identity":"f0a5660e-67d5-49d0-8b42-878f1e378496","order_by":12,"name":"Elise DELUCHE","email":"data:image/png;base64,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","orcid":"","institution":"Limoges University Hospital Center","correspondingAuthor":true,"prefix":"","firstName":"Elise","middleName":"","lastName":"DELUCHE","suffix":""}],"badges":[],"createdAt":"2024-01-23 06:59:14","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3890177/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3890177/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":50442145,"identity":"81ce5771-7e52-49f9-9cea-d42addea52ad","added_by":"auto","created_at":"2024-01-31 15:20:40","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":136661,"visible":true,"origin":"","legend":"\u003cp\u003eThe study timeline.\u003c/p\u003e\n\u003cp\u003eSolid line: normal management at the center. Dotted line: management during the study\u003c/p\u003e","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3890177/v1/280116845ea2062857299a3a.jpg"},{"id":50442144,"identity":"fac79c5e-e5ce-4892-9f3d-be0796ba8307","added_by":"auto","created_at":"2024-01-31 15:20:40","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":87885,"visible":true,"origin":"","legend":"\u003cp\u003eA study flow-chart.\u003c/p\u003e","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3890177/v1/acdda6cc362aededc3dea9a7.jpg"},{"id":61885203,"identity":"f1ab81de-a692-4881-afc5-9c8437cb678d","added_by":"auto","created_at":"2024-08-06 16:26:17","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1415132,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3890177/v1/2ec7f348-c3d5-4f4f-937c-d5ca7f3d8ed4.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"THERANOVA-LIM: Optimizing the city hospital link to support patients on oral anticancer drugs","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eRecent developments in oral chemotherapy and targeted therapies have radically changed the management of cancer patients [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Intravenous drugs were traditionally administered in the hospital, but outpatient oral cancer treatments are now developing rapidly, encouraging patients, families, and medical teams to reconsider the hospital-centric model of care [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. The French National Cancer Institute (INCa) estimated that the cost of anticancer drugs would attain 3.45\u0026nbsp;billion euro in 2021 [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e] and estimated that, by 2020, oral anticancer drugs would represent half of the therapeutic oncological arsenal [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. In 2018, more than 80 oral anticancer drugs were in the Oncology and Hematology pipeline [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Oral treatments offer several advantages that improve patient quality-of-life [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e] and well-being [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Patients usually prefer oral rather than intravenous drugs [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. However, it is necessary to guarantee safe use [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. The major risks include poor compliance, drug interactions, and toxicity [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Early detection of adverse effects can help avoid emergency hospitalization, non-adherence, or treatment discontinuation [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Healthcare organizations must be highly coordinated to ensure quality of care and patient safety as patients move between the city and the hospital [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Optimization of home care for cancer patients requires coordinated intervention by hospital and outpatient healthcare professionals who prevent, detect, and manage adverse events; avoid drug interactions; and counter drug misuse by educating patients, as advocated by the 2014\u0026ndash;2019 Cancer Plan [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Interdisciplinary coordination of various healthcare players is essential to ensure optimal care.\u003c/p\u003e \u003cp\u003eIn Limousin, the proportion of the population aged over 70 years is higher than the national average (19 vs. 11%) [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. In a recent evaluation performed during the COVID epidemic, we (of the oral therapy center) observed that one-third of patients were very comfortable with the new technologies, independent of caregiver opinions [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. At that time, preliminary work in our department highlighted the utility of a drug vigilance card. This improved the city-hospital link during the treatment of chronic lymphocytic leukemia and chronic myeloid and multiple myeloma [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. This work gave rise to the THERANOVA-LIM project (Oral Therapies in New Aquitaine and Limousin).\u003c/p\u003e \u003cp\u003eThe aim of this study was to evaluate communication between the city and the hospital via QR codes written on the drug vigilance cards or prescriptions of patients treated in the Onco-Hematology department. The QR codes provide information on new drugs to healthcare professionals, as do existing oral anticoagulant cards.\u003c/p\u003e"},{"header":"MATERIALS AND METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy design\u003c/h2\u003e \u003cp\u003eThe THERANOVA-LIM study was a prospective, descriptive, non-interventional, single-center study. Initially, one group of patients were given drug vigilance cards; later, another group were given prescriptions with QR codes. Phase 1 (drug vigilance card) patients were enrolled from November 08, 2021, to April 07, 2022, and phase 2 (prescription) patients from June 01, 2022, to August 30, 2022.\u003c/p\u003e \u003cp\u003eThe inclusion criteria were: treatment at the oral therapy center of the oncology department of Limoges University Hospital [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]; at least one oral chemotherapy and/or targeted therapy; and the ability to speak and understand French. The exclusion criteria were: endocrine therapy alone (excluding the new-generation therapies [abiraterone and enzalutamide] used to treat prostate cancer); injectable therapy alone; and a lack of Internet access required to activate the card, and/or a cell phone.\u003c/p\u003e \u003cp\u003eScanning the QR code directs the patient to a dedicated online platform [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e] and to the Association d'Oncologie M\u0026eacute;dicale et de Radioth\u0026eacute;rapie (AOMR) website that features cards and prescriptions [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Both patient groups could access written advice on the prescribed drugs and instructions for use prepared by our oncologist. For technical reasons, the sites for both groups differed. In contrast to the AOMR site, the card platform also contained patient medical information. The time course of the study is shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eObjectives and assessment criteria\u003c/h2\u003e \u003cp\u003eThe main objective was to measure patient satisfaction at 3 months (M3) using a paper or e-questionnaire with 12 questions adapted from the Computerized System Usability Questionnaire (CSUQ); all answers were scored on a 7-point Likert scale [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. The questions were adapted from previous publications [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. The secondary objectives were to measure patient compliance [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e] and the satisfaction of healthcare professionals at M3. A link to the e-questionnaire was sent via e-mail; the survey could be completed only once from that IP address. All questionnaire replies (online and paper) were anonymous.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eHuman Ethics and Consent to Participate\u003c/h2\u003e \u003cp\u003eThis research was carried out in compliance with the French law n\u0026deg;2012\u0026thinsp;\u0026minus;\u0026thinsp;300 of March 5, 2012 relating to research involving the human person and the Declaration of Helsinki (which can be found in its full version on the website \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.wma.net/en/30publications/10policies/b3/).Thi\u003c/span\u003e\u003cspan address=\"http://www.wma.net/en/30publications/10policies/b3/).Thi\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003es research was approved by the Comit\u0026eacute; de Protection des Personnes (approval no. 2021-A01230-41). The study is registered with ClinicalTrials.gov, NCT04931329. All patients enrolled in the study provided written informed consent.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eGiven the lack of data on this subject and on this new-generation card, it was decided to include all eligible patients. All data were collected and analyzed using R software (version 4.1.1; R Foundation for Statistical Computing, Vienna, Austria). Quantitative variables are expressed as numbers, medians with minima, and maxima, or means with standard deviations. Qualitative variables are expressed as numbers with percentages. To study the relationships between different variables (via bivariate analysis), we used the Mann-Whitney test to compare the scores of the two groups. The chi-square test was employed to compare qualitative variables. All significance thresholds were set to 5%. All patients who consulted during the study period and who met the eligibility criteria and wished to participate were included.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003ePreliminary survey of pharmacists\u003c/h2\u003e \u003cp\u003e An e-questionnaire was used to establish pharmacist practices and expectations; 46 pharmacists replied, of whom only 40.0% stated said they felt comfortable when managing a patient on oral therapy. Only 30 (62.0%) were familiar with the anticancer drug use sheets; 43.0% (n\u0026thinsp;=\u0026thinsp;15) consulted them regularly and 58.0% (n\u0026thinsp;=\u0026thinsp;19) printed them for patients when the drugs were first dispensed. Almost 20.0% (n\u0026thinsp;=\u0026thinsp;9) said they were in regular contact with the oncology department, and 69.6% (n\u0026thinsp;=\u0026thinsp;32) that they were contacted by patients who experienced adverse events related to cancer treatment. Only 8.7% (n\u0026thinsp;=\u0026thinsp;4) of city pharmacies scheduled oral therapy follow-up interviews within their business premises. Healthcare professionals lacked knowledge of and training on anticancer drugs, attributable to the rapid development of new agents and the complexity of the protocols. It was acknowledged that communication between independent professionals and hospital departments was suboptimal.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eClinicopathological characteristics of patients\u003c/h2\u003e \u003cp\u003eA total of 128 patients were included, 55 in the \u0026ldquo;drug vigilance card\u0026rdquo; and 73 in the \u0026ldquo;prescription with QR code\u0026rdquo; group (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). The clinicopathological characteristics are presented in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e and were comparable between the two groups. The median age at inclusion was 69 years (range 37\u0026ndash;90 years); there were 85 women and 43 men. The majority of patients lived as couples (89.1%) in single-family homes (87.3%), were retired (74.8%), and resided in the University Hospital Center area (64.6%). The three most common cancers were breast (37.5%), prostate (14.1%), and brain (10.9%) cancers. The vast majority of patients had metastatic cancer (90%) and grade IV gliomas (brain tumors) (85%).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eClinicopathological characteristics of patients\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWhole population\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePhase 1 (drug vigilance card)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003ephase 2 (prescription)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003ep-values\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTotal, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e128 (100)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e55 (43)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e73 (57)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMedian age at inclusion, years (min-max)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e69 (37\u0026ndash;91)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e69 (37\u0026ndash;91)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e70 (38\u0026ndash;89)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.1852\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eFemale/ Male\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e85 (66.4) / 43 (33.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39 (70.9) / 16 (29.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e46 (63.0) / 27 (37.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.4549\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePerformans status at baseline n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003e0\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e37 (28.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14 (25.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23 (31.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e0.4764\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003e1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75 (58.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36 (65.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e39 (53.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003e2\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e15 (11.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (9.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10 (13.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003e3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLifestyle*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSingle/ In couple\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e20 (15.9) / 106 (84.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (10.9) / 49 (89.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e14 (19.7) / 57 (80.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.2927\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eApartment/ house/ lodging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e14 (11.1) / 110 (87.3) / 2 (1.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (9.1) / 50 (90.9) / 0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9 (12.7) /60 (84.5) / 2 (2.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.3091\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLives in the University Hospital Center area\u003c/p\u003e \u003cp\u003eYes/No\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e82 (64.6) / 46 (35.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35 (63.6) / 20 (36.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e47 (64.4) / 33 (35.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRetired/ In work/ On disability\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e95 (74.8) / 27 (21.3) / 5 (3.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e40 (74.1) / 14 (25.9) / 0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e55 (75.3) / 13 (17.8) / 5 (6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.112\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCancer site n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCardia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"11\" rowspan=\"12\"\u003e \u003cp\u003e0.4232\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eColon\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10 (7.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (12.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3 (4.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEndometrium\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOvary\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e12 (9.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (9.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7 (9.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePancreas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (2.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (3.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eProstate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e18 (14.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (9.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13 (17.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRectum\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (2.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (1.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eKidney\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e12 (9.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (10.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6 (8.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBreast\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e48 (37.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21 (38.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e27 (37.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBrain tumors\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e14 (10.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (12.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7 (9.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAdrenal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (1.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBiliary tract\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (3.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (1.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3 (4.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eStage at inclusion of gliomas (n\u0026thinsp;=\u0026thinsp;14)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eGrade III\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (15)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.8534\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eGrade IV\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e12 (85)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6 (86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eStage at inclusion excluding gliomas (n\u0026thinsp;=\u0026thinsp;114)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eStade I-III\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11 (10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9 (14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003e0.0018\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eStade IV\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e103 (90)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e46 (96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e57 (86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMetastatic from the outset\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eNo\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e86 (67.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33 (60.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e53 (72.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.1891\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eYes\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e42 (32.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22 (40.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e20 (27.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSituation at baseline\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eAdjuvant setting\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e25 (19.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9 (16.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e16 (21.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.5758\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMetastatic settint\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e103 (80.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e46 (83.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e57 (78.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c6\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"6\"\u003e* Missing data\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eInclusion and follow-up\u003c/h2\u003e \u003cp\u003eThe treatments are shown in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e. The four most prescribed drugs were capecitabine (21.1%), ribociclib (11.7%), temozolomide (11.7%), and trifluridine/tipiracil (7.8%). In 43.0% of cases, it was necessary to modify the drug dose during the management. Of the phase 1 group, 83.6% attended hospital pharmaceutical appointments; the figure for the phase 2 group was 28.8% (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). The numbers of telephone calls made by the oral therapy center were identical for both groups. During the study, 25.0% of patients experienced grade III or IV toxicities that were reported to pharmacovigilance; 6 (4.7%) were admitted to the emergency department, 11 (8.6%) were hospitalized, and 10 (11.1%) had to permanently cease treatment. No toxic deaths occurred.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eTreatment received by the patients\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"8\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWhole population\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003ePhase 1 (drug vigilance card)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003ePhase 2 (prescription)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003ep-values\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTotal, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e128 (100)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e55 (43)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e73 (57)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eOral therapy, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAbemaciclib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5 (3.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e2 (3.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e3 (4.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"18\" rowspan=\"19\"\u003e \u003cp\u003e0.06865\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAbiraterone\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9 (7.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e4 (7.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e5 (6.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAxitinib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (4.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e3 (5.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e3 (4.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCabozantinib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (3.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e2 (3.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e2 (2.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCapecitabine\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27 (21.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e9 (16.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e18 (24.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEnzalutamide\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9 (7.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e1 (1.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e8 (11.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEverolimus\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (1.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e2 (3.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLenvatinib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNiraparib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9 (7.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e5 (9.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e4 (5.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOlaparib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (3.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e1 (1.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e3 (4.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePalbociclib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5 (3.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e1 (1.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e4 (5.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePazopanib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRegorafenib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e1 (1.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRibociclib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e15 (11.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e9 (16.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e6 (8.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSorafenib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSutinib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (1.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e1 (1.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTemozolomide\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e15 (11.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e7 (12.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e8 (11.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTrifluridine/tipiracil\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10 (7.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e6 (10.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e4 (5.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVinorelbine\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (1.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e1 (1.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePrescription procedures, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEarly access\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (1.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e2 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003e0.4113\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eClinical trial\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (1.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e1 (1.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRoutine pratice\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e124 (96.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e54 (98.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e70 (95.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAdjusting the dose of prescribed treatment, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e73 (57.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e29 (52.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e44 (60.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.5006\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e55 (43.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e26 (47.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e29 (39.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePharmaceutical consultation, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e61 (47.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e9 (16.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e52 (71.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003e\u0026lt;\u0026thinsp;0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e67 (52.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e46 (83.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e21 (28.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNumber of center calls, median (min-max)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (0\u0026ndash;20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e7 (0\u0026ndash;15)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003e6 (1\u0026ndash;20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.4868\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eToxicity III-IV reported to pharmacovigilance, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e96 (75.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e39 (70.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e57 (78.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c8\" namest=\"c7\" rowspan=\"2\"\u003e \u003cp\u003e0.4627\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e32 (25.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e16 (29.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e16 (21.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"8\" nameend=\"c8\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEmergency room visits for toxicity, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e122 (95.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e52 (94.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e70 (95.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c8\" namest=\"c7\" rowspan=\"2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e6 (4.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e3 (5.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3 (4.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"8\" nameend=\"c8\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHospitalization for toxicity, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e117 (91.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e49 (89.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e68 (93.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c8\" namest=\"c7\" rowspan=\"2\"\u003e \u003cp\u003e0.6222\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e11 (8.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (10.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e5 (6.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"8\" nameend=\"c8\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePermanent discontinuation of treatment due to toxicity, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e80 (88.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e40 (88.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e40 (88.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c8\" namest=\"c7\" rowspan=\"2\"\u003e \u003cp\u003e0.0816\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e10 (11.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e5 (11.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e5 (11.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eAssessing patient satisfaction\u003c/h2\u003e \u003cp\u003eOf the 119 patients who could be evaluated (9 died during the study: 7 during phase 1 and 2 during phase 2), the questionnaire response rates were 37.0% (n\u0026thinsp;=\u0026thinsp;44); 25.0% (n\u0026thinsp;=\u0026thinsp;12/48) for phase 1 and 45.0% (n\u0026thinsp;=\u0026thinsp;32/71) for the phase 2 groups (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). The principal results are shown in Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e. Patients in both groups were generally satisfied with the system and the ease of use of both the card and the prescription (p\u0026thinsp;=\u0026thinsp;0.9). Of patients with QR codes on vigilance cards, 100% presented their cards to dispensing pharmacists, 28.6% to referring GPs, and 28.6% to home care nurses. The occasions on which patients presented cards included medical consultations (25.0%), visits to the pharmacy (100%), and when the homecare nurse was in attendance (25.0%). Patients with QR codes on their prescriptions presented those prescriptions in 72% of cases, 88.5% (n\u0026thinsp;=\u0026thinsp;23/26) to dispensing pharmacists, 36.0% (n\u0026thinsp;=\u0026thinsp;9/25) to GPs, and 29.6% (n\u0026thinsp;=\u0026thinsp;8/27) to home care nurses. The occasions on which patients presented cards included medical consultations (33.3%), visits to the pharmacy (81.5%), when the homecare nurse was present (70.4%), during hospitalization (7.4%), and in emergency situations (3.7%).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePatient satisfaction at 3 months.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eWhole population\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003ePhase 1\u003c/p\u003e \u003cp\u003e(drug vigilance card)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003ePhase 2 (prescription)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003ep-value\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTotal, n (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e44 (100)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e12 (27)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e32 (72)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e1. In general, I'm satisfied with this system (n\u0026thinsp;=\u0026thinsp;37)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e7 (2\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (5\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e7 (2\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.8970\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e2. In general, I'm satisfied with the ease of use of this system (n\u0026thinsp;=\u0026thinsp;36)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e7 (2\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e7 (2\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.4603\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e3. This system is easy to use (n\u0026thinsp;=\u0026thinsp;36)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e7 (2\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e7 (3\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e7 (2\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.3922\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e4. I feel comfortable with this system (n\u0026thinsp;=\u0026thinsp;37)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e6 (1\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e7 (1\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.6732\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e5. It was easy to understand how to use this system (n\u0026thinsp;=\u0026thinsp;37)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e6 (1\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (3\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e7 (1\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.6265\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e6. When I made a mistake, it was quick and easy to correct it (n\u0026thinsp;=\u0026thinsp;34)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e7. I easily found the information I was looking for (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e6 (2\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (5\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e7 (2\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.8348\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e8. The system's information is easy to understand (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e7 (2\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (5\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e7 (2\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.9308\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e9. System screens are clearly organized (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e10. L\u0026rsquo;interface de ce syst\u0026egrave;me est agr\u0026eacute;able (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e11. I like using the interface of this system (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e12. This system has all the functions and potential I was looking for (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e7 (1\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e6 (4\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e7 (1\u0026ndash;7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.8621\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e13. Did you show your card/prescription?\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20.5%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e41.7%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e12.5%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.0661\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e79.5%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e58.3%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e87.5%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e14. If yes, have you shown it to your doctor? (n\u0026thinsp;=\u0026thinsp;32)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e65.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e71.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e64%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.3988\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e28.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e36%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003eIf so, have you shown it to your pharmacist? (n\u0026thinsp;=\u0026thinsp;33)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9.1%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e11.5%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.2026\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e90.9%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e88.5%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003eIf so, did you show it to your nurse? (n\u0026thinsp;=\u0026thinsp;34)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e71.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e70.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.1852\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e28.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e29.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003eIf yes, I have shown it during hospitalization (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e94.3%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e92.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.3262\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.7%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003eIf yes, I've shown it in emergency situations (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e97.1%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e96.3%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.3766\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.9%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3.7%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003eIf yes, I showed it during a consultation (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e68.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e66.7%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.3948\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e31.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e25%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e33.3%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003eIf so, I showed it to the pharmacy: (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14.3%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e18.5%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e85.7%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e81.5%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003eIf yes, did I show it to my nurse? (n\u0026thinsp;=\u0026thinsp;35)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e71.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e70.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.419\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e28.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e25%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e29.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e15. Has this prescription/card helped you remember to take your medication? (n\u0026thinsp;=\u0026thinsp;31)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e5 (1\u0026ndash;10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e5 (1\u0026ndash;10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e5 (1\u0026ndash;10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.2826\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003e16. Has the presence of a QR code on this card/ prescription been useful? (n\u0026thinsp;=\u0026thinsp;31)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (min-max)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e7 (1\u0026ndash;10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e7 (1\u0026ndash;10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e5 (1\u0026ndash;10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.8635\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003eNA : not applicable\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003eQuestionnaire based on a 7-point Likert scale ranging from disagreement (0) to total agreement (7) and 10 points (*).\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eThe satisfaction of healthcare professionals\u003c/h2\u003e \u003cp\u003eA total of 74 evaluations were collected (Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e). Healthcare professionals were equally satisfied with the two QR code systems (100% vs. 91.7%). The QR code affixed to the prescription was, however, easier to access (64.3% vs. 91.7%, p\u0026thinsp;=\u0026thinsp;0.02).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eThe satisfaction of healthcare professionals at 3 months.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWhole population\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePhase 1 (drug vigilance card)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePhase 2 (prescription)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003ep-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTotal, n (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003e74 (100)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14 (18.9)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e60 (81)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eDid you know that your patient has a drug card / prescription with QR code?\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13 (17.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13 (21.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.1274\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e61 (82.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14 (100)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e47 (78.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eHas your patient shown you his drug card/prescription with QR code?\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e31 (41.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9 (64.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e22 (36.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.1129\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e43 (58.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (35.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e38 (63.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eDid the card or QR code prescription have an impact on this patient's care?\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e26 (35.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (21.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23 (38.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.3777\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e48 (64.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11 (78.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e37 (61.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eIf yes. has it had an impact on treatment information and management?\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11 (23.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (45.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6 (17.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.1298\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e35 (76.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (54.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e29 (82.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eIf yes. has it had an impact on the risks associated with this treatment? *\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (18.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4 (11.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.9466\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e40 (87)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9 (81.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e31 (88.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eIf yes. did it have an impact on information on how to proceed with this treatment? *\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10 (21.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4 (36.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6 (17.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.3528\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e36 (78.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (63.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e29 (82.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eIn general. I'm satisfied with this system\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5 (6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5 (8.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e.5980\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e69 (93.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14 (100)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e55 (91.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eIn general. I'm satisfied with the ease of use of this system\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10 (13.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (35.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5 (8.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003e.0246\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e64 (86.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9 (64.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e55 (91.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003e* 2 missing data\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eCompliance\u003c/h2\u003e \u003cp\u003eThe compliance rates were 75.0% in the phase 1 group (n\u0026thinsp;=\u0026thinsp;9/12) (drug vigilance card) and 59.4% (n\u0026thinsp;=\u0026thinsp;19/32) in the phase 2 group (QR code on prescription); compliance rates did not differ significantly (p\u0026thinsp;=\u0026thinsp;0.4).\u003c/p\u003e \u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003e We sought to strengthen the city-hospital link by placing a QR code on either a drug vigilance card or a prescription written by the oncology department, and we showed the feasibility of the approach. In terms of both ease of implementation and the satisfaction of healthcare professionals, the QR-coded prescription was optimal. Digitization in cases of complex care required by patients with chronic illnesses, particularly cancer, is essential [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. Efforts to improve information sharing and coordination between hospitals and patients/pharmacists have been underway for several years. Cards have been developed for patients on anticoagulants [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. The Dijon and Besan\u0026ccedil;on university hospitals have created \u0026ldquo;identity cards\u0026rdquo; for diabetics [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e] that feature a QR code indicating the required treatment, particularly in the event of an emergency [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. The QR code system has been but little used by oncologists who require access to medical data or specific patient information. [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. In our model, we integrated treatment information, data on urgent toxicity management, and advice; we sought to increase patient compliance. In the absence of medical consultation, a pharmacy is the place where health professionals are available without appointment; pharmacists must have timely and detailed information to ensure optimal care. Pharmacies are widespread and play key roles in care, particularly when patients require security and support.\u003c/p\u003e \u003cp\u003eThe coded QR card may seem interesting, particularly in terms of its format, because patients can carry coded QR cards at all times, but this does not mean that they are autonomous. Both the digital divide and difficulties in accessing technology are still in play. Even the average age of our population is similar to that nationally [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e], the impact of age and access to new technologies must be particularly taken into account. Some studies on remote monitoring, particularly of oral therapy, included much younger patients [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. For example, in the Capri study, the median age was 62 years (range 20\u0026ndash;92 years); 27.7% of patients were aged between 65 and 74 years and 14% over 75 years [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. The proportions of patients who use new technologies, particularly smartphone applications, are often age-dependent [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]. On the contrary, prescriptions are easy to use at any age. A limitation of the QR code system for prescription is that it applies only to drugs dispensed in hospitals, not community pharmacies, the staff of which thus lack knowledge of cancer treatments such as temozolomide.\u003c/p\u003e \u003cp\u003eWebsite and smartphone applications aid symptom management. In a review, Penedo et al. found that e-Health technologies aided cancer treatment [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. However, if such systems are exclusively patient-centric, they will not be accessible by healthcare professionals. We cannot assess whether the use of QR codes reduced the incidence and impact of toxicity; the study was not designed to answer this question. However, the toxicity rate of 25.0% is in line with the literature [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] and the number of toxicity management calls was lower than in our previous publication [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eWe thus highlight that healthcare professionals must improve city-hospital relationships and establish secure information systems for oral therapy [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e, \u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. Communication among healthcare professionals is vital [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]; presently, no optimal support system is available [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. Occhipinti et al. showed that, although 44.4% of institutions had established city-hospital coordination, all found that this was time-consuming [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe monocentric nature of the present study is one limitation, particularly in terms of representativeness. The fact that the study was performed in two successive phases reflects technical imperatives; it was necessary both to create cards and develop software that placed QR codes on prescription. Moreover, self-questionnaires may introduce information bias. Indeed, some patients chose not to answer certain questions. In addition, a Hawthorne effect may be in play; patients who are aware that they are being surveyed may (consciously or unconsciously) overestimate their compliance rates [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e]. Recruitment bias may be in play; many patients had brain tumors (our center has expertise in this field) [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. However, unlike other studies, we did not select particular types of tumors and the QR code was available to all cancer patients.\u003c/p\u003e"},{"header":"CONCLUSION","content":"\u003cp\u003eWe evaluated two systems with integrated QR codes (with prescription or cards); the prescription was preferred by both patients and professionals. This provides access to information on the correct and safe use of drugs. We developed a website that distributes QR codes free of charge; those who prescribe cancer treatment can place specific QR codes on their prescriptions. Once flashed, the QR codes redirects to the advice sheets on the websites of learned societies and official organizations. After scanning the QR codes on prescriptions, patients, caregivers, and healthcare professionals instantly access advice sheets. The system will be evaluated further by healthcare professionals. \u0026nbsp;The increased availability of most oral anticancer drugs outside hospitals requires greater collaboration between hospital and primary care professionals, particularly dispensing pharmacists. It is essential to improve the continuity of care.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eData availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eData are available from the corresponding author upon reasonable request\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of Interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no conflict of interest in relation to this \u0026nbsp;study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was funded by the Ligue Contre le Cancer, ALAIR, Accord Pharmafield, AstraZeneca, Janssen, Seagen, Cr\u0026eacute;dit Mutuel Loire-Atlantique, and the ERRE family.\u003c/p\u003e\n\u003cp\u003eThe English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/yM1QiD\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAUTHOR CONTRIBUTIONS\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eConceptualisation, E.D.; methodology, E.D.,SL.; formal analysis, S.L .; writing - original draft preparation, M.B, E.D, S,L.; writing - review and editing, M.B, S.L, K-A.B,T.D,C.P, V.L-B, J.P, L.V, F.T S.H, J.J,M.T,E.D ; supervision, E.D. All authors have read and agreed to the published version of the manuscript.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eO\u0026rsquo;Neill VJ, Twelves CJ (2002) Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 87:933\u0026ndash;937. https://doi.org/10.1038/sj.bjc.6600591\u003c/li\u003e\n\u003cli\u003eBosco-L\u0026eacute;vy P, de Boissieu P, Gouverneur A, et al (2017) National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study. Pharmacoepidemiol Drug Saf 26:1233\u0026ndash;1241. https://doi.org/10.1002/pds.4282\u003c/li\u003e\n\u003cli\u003eMoreira A, Bernardo C, Ramos C, et al (2022) National trends in the use of oral chemotherapy over 13 years. Front Pharmacol 13:909948. https://doi.org/10.3389/fphar.2022.909948\u003c/li\u003e\n\u003cli\u003eChiffres cl\u0026eacute;s de la chimioth\u0026eacute;rapie - Chimioth\u0026eacute;rapie. https://www.e-cancer.fr/Professionnels-de-sante/Les-traitements/Chimiotherapie/Chiffres-cles-de-la-chimiotherapie. Accessed 9 Sep 2023\u003c/li\u003e\n\u003cli\u003ePlan Cancer 2014-2019 - Ref : PLANKPNRT14. https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Plan-Cancer-2014-2019. Accessed 9 Sep 2023\u003c/li\u003e\n\u003cli\u003eLe Plan cancer 2014-2019 - Les Plans cancer\u003c/li\u003e\n\u003cli\u003eJacobs JM, Ream ME, Pensak N, et al (2019) Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life. J Natl Compr Cancer Netw JNCCN 17:221\u0026ndash;228. https://doi.org/10.6004/jnccn.2018.7098\u003c/li\u003e\n\u003cli\u003eEilers J, Million R (2011) Clinical update: prevention and management of oral mucositis in patients with cancer. Semin Oncol Nurs 27:e1-16. https://doi.org/10.1016/j.soncn.2011.08.001\u003c/li\u003e\n\u003cli\u003eRubenstein EB, Peterson DE, Schubert M, et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026\u0026ndash;2046. https://doi.org/10.1002/cncr.20163\u003c/li\u003e\n\u003cli\u003eEek D, Krohe M, Mazar I, et al (2016) Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence 10:1609\u0026ndash;1621. https://doi.org/10.2147/PPA.S106629\u003c/li\u003e\n\u003cli\u003eRanchon F, Bouret C, Charpiat B, Leboucher G (2009) S\u0026eacute;curisation de l\u0026rsquo;emploi des chimioth\u0026eacute;rapies anticanc\u0026eacute;reuses administrables par voie orale. Pharm Hosp 44:36\u0026ndash;44. https://doi.org/10.1016/j.phhp.2008.12.002\u003c/li\u003e\n\u003cli\u003eMasson E Parcours de soins : mod\u0026eacute;lisation et analyse des risques induits par les anticanc\u0026eacute;reux oraux. In: EM-Consulte. https://www.em-consulte.com/article/1048739/parcours-de-soins�-modelisation-et-analyse-des-ris. Accessed 5 Sep 2023\u003c/li\u003e\n\u003cli\u003ePalmer DH, Johnson PJ (2015) Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. Cancer Metastasis Rev 34:497\u0026ndash;509. https://doi.org/10.1007/s10555-015-9580-2\u003c/li\u003e\n\u003cli\u003eSchneider SM, Hess K, Gosselin T (2011) Interventions to promote adherence with oral agents. Semin Oncol Nurs 27:133\u0026ndash;141. https://doi.org/10.1016/j.soncn.2011.02.005\u003c/li\u003e\n\u003cli\u003ePyramide des \u0026acirc;ges. //extranet.dst.dk/websites/pyramide/pyramide.htm. Accessed 9 Sep 2023\u003c/li\u003e\n\u003cli\u003eBaffert K-A, Darbas T, Lebrun-Ly V, et al (2021) Quality of Life of Patients With Cancer During the COVID-19 Pandemic. In Vivo 35:663\u0026ndash;670. https://doi.org/10.21873/invivo.12306\u003c/li\u003e\n\u003cli\u003eTouati M, Dumond-Wibaux \u0026Eacute;, Jeannet L, et al (2018) Carte vigilance m\u0026eacute;dicament : le patient acteur de sa prise en charge\u003c/li\u003e\n\u003cli\u003eDeluche E, Darbas T, Bourcier K, et al (2020) Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme). Med Oncol 37:69. https://doi.org/10.1007/s12032-020-01393-7\u003c/li\u003e\n\u003cli\u003eDeluche E, Darbas T, Bourcier K, et al (2020) CN46 Real-life experience of nurses coordinating device in oral therapy center (DICTO program). Ann Oncol 31:S1141. https://doi.org/10.1016/j.annonc.2020.08.2156\u003c/li\u003e\n\u003cli\u003eID1life website. In: ID1 - Infos Urgence. https://www.id1.life/. Accessed 9 Sep 2023\u003c/li\u003e\n\u003cli\u003eAOMR website. https://www.cancer-limoges.fr/centre-des-therapies-orales/role-et-fonctionnement-du-cto. Accessed 9 Sep 2023\u003c/li\u003e\n\u003cli\u003eIBM computer usability satisfaction questionnaires: Psychometric evaluation and instructions for use: International Journal of Human\u0026ndash;Computer Interaction: Vol 7, No 1. https://www.tandfonline.com/doi/abs/10.1080/10447319509526110. Accessed 2 Sep 2023\u003c/li\u003e\n\u003cli\u003ePoinsot R, Altmeyer A, Conroy T, et al (2006) [Multisite validation study of questionnaire assessing out-patient satisfaction with care questionnaire in ambulatory chemotherapy or radiotherapy treatment]. Bull Cancer (Paris) 93:315\u0026ndash;327\u003c/li\u003e\n\u003cli\u003eGIRERD X, HANON O, ANAGNOSTOPOULOS K, et al (2001) Evaluation de l\u0026rsquo;observance du traitement antihypertenseur par un questionnaire : mise au point et utilisation dans un service sp\u0026eacute;cialis\u0026eacute;. Eval Obs Trait Antihypertenseur Par Un Quest Mise Au Point Util Dans Un Serv Sp\u0026eacute;c 30:1044\u0026ndash;1048\u003c/li\u003e\n\u003cli\u003eSteinhubl SR, Muse ED, Topol EJ (2013) Can Mobile Health Technologies Transform Health Care? JAMA 310:2395\u0026ndash;2396. https://doi.org/10.1001/jama.2013.281078\u003c/li\u003e\n\u003cli\u003eGras-Champel V, Voyer A, Lematte C, et al (2005) Evaluation \u0026agrave; l\u0026rsquo;occasion de leur hospitalisation de la qualit\u0026eacute; de l\u0026rsquo;anticoagulation orale chez des patients trait\u0026eacute;s par antivitamines K. Therapies 60:149\u0026ndash;157. https://doi.org/10.2515/therapie:2005019\u003c/li\u003e\n\u003cli\u003eDiabete-Infos (2019) Carte iDiab\u0026egrave;te. In: Diab\u0026egrave;te Infos. https://diabete-infos.fr/carte-idiabete/. Accessed 5 Sep 2023\u003c/li\u003e\n\u003cli\u003eurps-secretariat Lancement de la carte iDiab\u0026egrave;te \u0026ndash; URPS. https://urps-pharmaciens-bfc.com/lancement-de-la-carte-idiabete/. Accessed 5 Sep 2023\u003c/li\u003e\n\u003cli\u003eUpton J, Olsson-Brown A, Marshall E, Sacco J (2017) Using QR codes to enable quick access to information in acute cancer care. Br J Nurs 26:S4\u0026ndash;S12. https://doi.org/10.12968/bjon.2017.26.10.S4\u003c/li\u003e\n\u003cli\u003eMittal A, Kum F, Rice M, et al (2022) An innovative use of Quick Response codes to provide patients information in Urology. J Clin Urol 20514158221092183. https://doi.org/10.1177/20514158221092183\u003c/li\u003e\n\u003cli\u003eMir O, Ferrua M, Fourcade A, et al (2022) Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med 28:1224\u0026ndash;1231. https://doi.org/10.1038/s41591-022-01788-1\u003c/li\u003e\n\u003cli\u003eGirault A, Ferrua M, Lallou\u0026eacute; B, et al (2015) Internet-based technologies to improve cancer care coordination: current use and attitudes among cancer patients. Eur J Cancer Oxf Engl 1990 51:551\u0026ndash;557. https://doi.org/10.1016/j.ejca.2014.12.001\u003c/li\u003e\n\u003cli\u003ePotdar R, Thomas A, DiMeglio M, et al (2020) Access to internet, smartphone usage, and acceptability of mobile health technology among cancer patients. Support Care Cancer 28:5455\u0026ndash;5461. https://doi.org/10.1007/s00520-020-05393-1\u003c/li\u003e\n\u003cli\u003eBizot A, Karimi M, Rassy E, et al (2021) Multicenter evaluation of breast cancer patients\u0026rsquo;\u0026rsquo; satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. Br J Cancer 125:1486\u0026ndash;1493. https://doi.org/10.1038/s41416-021-01555-y\u003c/li\u003e\n\u003cli\u003ePenedo FJ, Oswald LB, Kronenfeld JP, et al (2020) The increasing value of eHealth in the delivery of patient-centred cancer care. Lancet Oncol 21:e240\u0026ndash;e251. https://doi.org/10.1016/S1470-2045(20)30021-8\u003c/li\u003e\n\u003cli\u003eRenard P-Y (2013) D\u0026eacute;livrance des anticanc\u0026eacute;reux oraux : besoins et attentes du pharmacien d\u0026rsquo;officine. Actual Pharm 52:44\u0026ndash;47. https://doi.org/10.1016/j.actpha.2012.12.005\u003c/li\u003e\n\u003cli\u003eAbbott R, Edwards S, Whelan M, et al (2014) Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada. J Oncol Pharm Pract 20:29\u0026ndash;39. https://doi.org/10.1177/1078155213504975\u003c/li\u003e\n\u003cli\u003eMaritaz C, Gault N, Roy C, et al (2019) Impact d\u0026rsquo;une organisation r\u0026eacute;gionale coordonn\u0026eacute;e pour s\u0026eacute;curiser la prise en charge des patients sous anticanc\u0026eacute;reux oraux : CHIMORAL, une \u0026eacute;tude comparative. Bull Cancer (Paris) 106:734\u0026ndash;746. https://doi.org/10.1016/j.bulcan.2019.03.019\u003c/li\u003e\n\u003cli\u003eSeguin L, Tassy L (2022) E-sant\u0026eacute;, digitalisation ou transformation num\u0026eacute;rique : impact sur les soins de support en oncologie. Bull Cancer (Paris) 109:598\u0026ndash;611. https://doi.org/10.1016/j.bulcan.2021.08.015\u003c/li\u003e\n\u003cli\u003eOcchipinti S, Petit-Jean E, Pinguet F, et al (2017) Implication du pharmacien dans l\u0026rsquo;accompagnement des patients sous anticanc\u0026eacute;reux oraux : \u0026eacute;tat des lieux dans les centres de lutte contre le cancer (CLCC). Bull Cancer (Paris) 104:727\u0026ndash;734. https://doi.org/10.1016/j.bulcan.2017.06.012\u003c/li\u003e\n\u003cli\u003eRuddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56\u0026ndash;66. https://doi.org/10.3322/caac.20004\u003c/li\u003e\n\u003cli\u003ePinet S, Durand S, Perani A, et al (2023) Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital. Front Oncol 13:1104659. https://doi.org/10.3389/fonc.2023.1104659\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Oral therapy, cancer, targeted therapies, chemotherapy, compliance, safety","lastPublishedDoi":"10.21203/rs.3.rs-3890177/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3890177/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003ePurpose:\u003c/strong\u003e Recent developments in oral chemotherapy and targeted therapies have radically changed the way in which cancer patients are managed. Ambulatory care is now common, associated with the development of organizations that foster, secure home treatments, and reinforce the city hospital link.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods: \u003c/strong\u003eTHERANOVA-LIM (NCT04931329), a prospective, interventional study, assessed the satisfaction of healthcare professionals and patients who benefited from improved access to information on appropriate drug use imparted by a drug vigilance card or a prescription with a QR code.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults:\u003c/strong\u003e Initially, an e-questionnaire was used to explore the practices and expectations of retail pharmacists; only 40% stated that they felt comfortable when managing patients on oral therapy. A total of 128 patients were included in the study, 55 in a “medication vigilance card” group and 73 in a “prescription with QR code” group. Patients were satisfied with the new systems and with the simplicity afforded by both the card and the prescription (p = 0.8). Similarly, 93.2% of professionals were satisfied with the new system. However, they felt that the prescription with a QR code was of greater assistance than the drug vigilance card (p = 0.02). There was no significant between-group difference in compliance (p = 0.3595)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion:\u003c/strong\u003e The two systems improved the management of patients on oral chemotherapy; the QR-coded prescription was optimal. The fact that both patients and healthcare professionals were satisfied encourages us to extend the innovations and evaluate them further.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTrial Registration Number and the date of registration:\u003c/strong\u003e ClinicalTrials.gov, NCT04931329. \u0026nbsp;2021-05-10\u003c/p\u003e","manuscriptTitle":"THERANOVA-LIM: Optimizing the city hospital link to support patients on oral anticancer drugs","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-01-31 15:20:35","doi":"10.21203/rs.3.rs-3890177/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"d47f9795-45ed-4b8f-ae19-2a0b20592020","owner":[],"postedDate":"January 31st, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-08-06T16:18:10+00:00","versionOfRecord":[],"versionCreatedAt":"2024-01-31 15:20:35","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3890177","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3890177","identity":"rs-3890177","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}